Drugs / ECC0509
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT05012423 | Jul 2021 → Jul 2023 | metabolic dysfunction-associated steatohepatitis, osteoarthritis | Eccogene | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT07288138 | Dec 2025 → Sep 2027 expected | metabolic dysfunction-associated steatohepatitis | Eccogene | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 2
| Date | Issuer | Release |
|---|---|---|
| 2025-10-06 | Eccogene | Regulatory Eccogene Receives U.S. FDA Clearance to Initiate Phase 2a MOSAIC Trial of ECC4703 and ECC0509 for MASH eccogene.com ↗
We are pleased to receive the FDA clearance to initiate our Phase 2a MOSAIC trial with ECC4703 and ECC0509 for MASH, which impacts millions of patients worldwide, said Jingye Zhou, Chief Executive Officer of Eccogene. |
| 2024-11-15 | Eccogene | Results Eccogene Announces Positive Phase 1 Data for Oral THR-β Full Agonist and Oral SSAO Inhibitor in Late-Breaking Poster Presentations at the American Association for the Study of Liver Diseases (AASLD) The Liver Meeting® eccogene.com ↗
Both ECC4703 and ECC0509 demonstrated best-in-class potential, with favorable safety and tolerability profiles, clear target engagement and encouraging efficacy signals |
All press releases naming this drug 4 releases
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ECC0509 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07288138 ↗ |
| Action | Inhibit | “an SSAO Inhibitor (ECC0509)” NCT07288138 ↗ |
| Route | Oral | “administered as oral capsules” NCT05012423 ↗ |